News Hub | News Direct

Kadimastem Raises $5 million In Private Placement

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today a NIS 16.1 million ($5 million) private placement, led by funds Clover Wolf Capital and Alpha Capital Anstalt and with the additional investment in the company by its controlling shareholders, Professor Michel Revel and Mr. Julien Ruggieri. In addition to the placement announced today, the investors were also given an option to purchase an additional NIS 15.1 million ($4.7 million) in shares in the future. Today’s investment will be used to support Kadimastem’s future clinical trial activity and fund multiple strategic collaborations involving both the company’s ALS and Diabetes programs. The options were granted to the funds as part of a share issue from last April 2021. Clover Wolf has exercised 1,232,395 options and Alpha Capital has exercised 1,161,972 options both at an exercise price of 3.5 shekels ($1.1). This exercise of options took place approximately 10 months before the expiration date and amounted to about NIS 9.45 million ($2.9 million) for the company. The original exercise date of the options was July 31, 2022. Following the transaction, Clover Fund has increased its holding to approximately 20.6% of the company, while Alpha Capital has increased its holding to approximately 10.7% of the company. Following the additional investment by Professor Michel Revel and Mr. Julien Ruggieri, their holdings percentage has increased to 41.9% collectively. Company founder and controlling shareholder Professor Michel Revel exercised options amounting to NIS 3.5 million ($1.1 million) about a month ago. Following last month’s exercise of options, Professor Revel now holds approximately 31% of the company's shares. The round announced today follows a successful raise of NIS 22.3 million ($6.8 million) last April 2021. It’s also part of a series of company successes over the past year, including the meeting with the FDA (INTERACT) earlier this month regarding IsletRx, the company's stem cell-based technology for the treatment and potential cure of diabetes, the receipt of a Japanese patent for IsletRx, and the publishing of a scientific paper in the prestigious, peer-reviewed journal Frontiers in Endocrinology on the company’s advances in stem cell technology for the treatment and potential cure for diabetes. Kadimastem CEO Asaf Shiloni said, “Today’s funding will boost the speed of implementation of Kadimastem’s development strategy and enable us to safely fund our preparation for the clinical trials next year in the US. We are building a company that will lead the field of cell therapy, and the right mix of investors, who believe in the company’s path, is critical to enabling us to successfully implement our ambitious programs.” Chairman of the Board of Directors of Kadimastem Ronen Twito said, “We are very pleased with today’s significant private placement, which comes only six months after the Clover Wolf Capital and Alpha Capital Anstalt funds joined as shareholders. The funds have expressed confidence in us for the second time, and at a company value significantly higher than that determined in the previous round. Along with the investment of the controlling shareholders, Professor Michel Revel and Mr. Julian Ruggieri, this is an exceptional expression of trust in the company’s management, assets, progress and quality of science. We will continue to professionally lead Kadimastem to further success as well as maintain clear communication with and bring value to our shareholders." About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021 where the diabetes treatment program was discussed and the company received directions how to prepare its Pre-IND submission. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Herzl +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

October 26, 2021 01:49 AM Eastern Daylight Time

Image

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today a NIS 16.1 million ($5 million) private placement, led by funds Clover Wolf Capital and Alpha Capital Anstalt and with the additional investment in the company by its controlling shareholders, Professor Michel Revel and Mr. Julien Ruggieri. In addition to the placement announced today, the investors were also given an option to purchase an additional NIS 15.1 million ($4.7 million) in shares in the future. Today’s investment will be used to support Kadimastem’s future clinical trial activity and fund multiple strategic collaborations involving both the company’s ALS and Diabetes programs. The options were granted to the funds as part of a share issue from last April 2021. Clover Wolf has exercised 1,232,395 options and Alpha Capital has exercised 1,161,972 options both at an exercise price of 3.5 shekels ($1.1). This exercise of options took place approximately 10 months before the expiration date and amounted to about NIS 9.45 million ($2.9 million) for the company. The original exercise date of the options was July 31, 2022. Following the transaction, Clover Fund has increased its holding to approximately 20.6% of the company, while Alpha Capital has increased its holding to approximately 10.7% of the company. Following the additional investment by Professor Michel Revel and Mr. Julien Ruggieri, their holdings percentage has increased to 41.9% collectively. Company founder and controlling shareholder Professor Michel Revel exercised options amounting to NIS 3.5 million ($1.1 million) about a month ago. Following last month’s exercise of options, Professor Revel now holds approximately 31% of the company's shares. The round announced today follows a successful raise of NIS 22.3 million ($6.8 million) last April 2021. It’s also part of a series of company successes over the past year, including the meeting with the FDA (INTERACT) earlier this month regarding IsletRx, the company's stem cell-based technology for the treatment and potential cure of diabetes, the receipt of a Japanese patent for IsletRx, and the publishing of a scientific paper in the prestigious, peer-reviewed journal Frontiers in Endocrinology on the company’s advances in stem cell technology for the treatment and potential cure for diabetes. Kadimastem CEO Asaf Shiloni said, “Today’s funding will boost the speed of implementation of Kadimastem’s development strategy and enable us to safely fund our preparation for the clinical trials next year in the US. We are building a company that will lead the field of cell therapy, and the right mix of investors, who believe in the company’s path, is critical to enabling us to successfully implement our ambitious programs.” Chairman of the Board of Directors of Kadimastem Ronen Twito said, “We are very pleased with today’s significant private placement, which comes only six months after the Clover Wolf Capital and Alpha Capital Anstalt funds joined as shareholders. The funds have expressed confidence in us for the second time, and at a company value significantly higher than that determined in the previous round. Along with the investment of the controlling shareholders, Professor Michel Revel and Mr. Julian Ruggieri, this is an exceptional expression of trust in the company’s management, assets, progress and quality of science. We will continue to professionally lead Kadimastem to further success as well as maintain clear communication with and bring value to our shareholders. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021 where the diabetes treatment program was discussed and the company received directions how to prepare its Pre-IND submission. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Herzl +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

October 25, 2021 08:09 AM Eastern Daylight Time

Image

AmeriLife Appoints Ford Stokes Senior Vice President, Annuity Marketing

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing annuity, life, and health insurance solutions, today announced that it has hired Ford Stokes as senior vice president, Annuity Marketing. Stokes, reporting to AmeriLife Chief Marketing Officer Ovi Vitas, is charged with providing expert marketing strategies and implementation to AmeriLife affiliates, with the goal of helping financial advisors grow their advisory, insurance and annuities business. Most recently, Stokes served as an advisor to AmeriLife affiliate V2 Financial Group, where he implemented an aggressive, strategic marketing approach that helped grow V2’s profit 113.78% year over year in 2021. At AmeriLife, Stokes will, among other responsibilities, help define AmeriLife’s annuity marketing value proposition across its distribution network; help affiliates better activate cross-selling opportunities for annuities and retirement planning solutions; and drive third-party credibility of appointed advisors through exclusive thought leadership programs. "I can't wait to get started supporting AmeriLife’s affiliates and their advisors,” said Stokes. “Our affiliates work hard to protect and grow the hard-earned and hard-saved assets of their clients, while also ensuring they can help generate critical income for their clients’ retirement futures. We will work just as hard to help them help more Americans build a sound, successful retirement.” "Ford brings to AmeriLife a significant amount of consumer and financial industry expertise, business knowledge, and strategic acumen,” added Vitas. “I couldn’t be more excited to have Ford join the team, and I would encourage any financial advisor or insurance agent to get appointed with one of our affiliates to take advantage of the incredible expertise and qualified prospects that Ford and our team can provide.” Prior to joining AmeriLife, Stokes served as the chief marketing officer with a $2B independent marketing organization and was a former minority owner of a $3.4B registered investment advisor. He will continue to maintain his private wealth management practice based in Atlanta. Stokes earned his bachelor’s degree and MBA from Auburn University; holds a Series 65 Securities license; and is a licensed life and health insurance agent in Georgia, Alabama, Florida, Texas and North Carolina. Stokes resides in Atlanta with his wife Diana and their twin girls, Grace and Madison. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. By putting its mission into practice, AmeriLife has become recognized as a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees. For 50 years, AmeriLife has partnered with the nation’s leading insurance carriers to provide value and quality to customers served through a national distribution network of over 250,000 insurance agents and advisors, over 40 marketing organizations, and nearly 50 insurance agency locations. Visit www.AmeriLife.com and follow AmeriLife on Facebook and LinkedIn for more information. Contact Details Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Company Website https://amerilife.com/

October 22, 2021 10:00 AM Eastern Daylight Time

Image

AROYA Enhances Cannabis Production Platform with New Mobile Dashboard

AROYA, a division of METER Group, Inc.

AROYA, a METER Group company, today introduced AROYA Kiosk, a new cultivation dashboard for tablets, further adding precision, speed, and accuracy to cannabis cultivation. AROYA is the preferred cannabis production platform (CPP) of top cannabis operators across the country, combining innovative hardware and software to deliver actionable insights that help improve their yield in grams, per square foot, per year – predictably, profitably, and at scale. AROYA’s cannabis cultivation solutions foster data-driven decision making, improving yields and operational efficiency while normalizing product quality. Kiosk provides cultivators with unfettered, real-time visibility of all production activity from every grow room or site, simultaneously. End-to-end encryption enhances security and pin-protected access lets growers control access to sensitive information and review upcoming tasks for themselves or by room. The new mobile dashboard provides hyper-accurate readouts of measurements in both the substrate and the environment. It also gives a populated task schedule, as well as real-time alerts that allow Master Growers to monitor and adapt every aspect of the production process. AROYA’s already robust cannabis production platform offering helps stakeholders understand and improve cannabis production processes from seed to sale while driving consistent, scalable success with features like harvest group planning, tasks, alerts, a digital grow journal, recipes – and much more. Demand for cultivation and production platforms like AROYA that utilize Internet of Things (IoT) sensors, artificial intelligence, and data analytics is spiking. Analysts from AheadInsight project that the cannabis technology industry will continue to grow exponentially at a CAGR of 33.17 percent and attain a market value of $107.67 billion by 2025. “Our goal is to empower cannabis growers and cultivators with the competitive advantage that comes from end-to-end visibility and real-time access to data that drives actionable insights,” said Philip Malmquist, General Manager of AROYA. “Putting it together on a single dashboard gives growers all the information they need to make informed decisions that help them cultivate consistently higher quality cannabis, and improved grams per square foot per year.” Attending MJBizCon 2021? Visit AROYA at BOOTH C4418. ABOUT AROYA AROYA is a cannabis production platform that combines industry-leading hardware and software to help cultivators increase yield, scale operations, and achieve consistent quality. Based in Pullman, Washington, and a division of METER Group, Inc., AROYA optimizes and demystifies the entire cannabis production process from seed to package. For additional information, please visit www.AROYA.io Contact Details JMRConnect: Shaping Influence PR Mostafa Razzak +1 202-904-2048 m.razzak@jmrconnect.net Company Website https://aroya.io/

October 21, 2021 09:34 AM Eastern Daylight Time

New Plant Nutrient Analysis at MCR Labs Can Help Growers Save Money and Improve Yield

MCR Labs

MCR Labs is now offering a Plant Nutrient Analysis to home growers and commercial cannabis cultivators. The test provides cannabis growers with a detailed breakdown of the presence and concentration of 11 micro and macronutrients found within the tissue of submitted plant samples. MCR Labs is a licensed independent testing lab providing compliance testing to marijuana establishments, but Plant Nutrient Analysis is an optional screen not required for compliance testing of legal cannabis products. This test is designed to help growers improve plant health and productivity, optimize cultivation practices, and cut costs related to supplemental nutrient feeding. “Nutrient analysis offers a lot of beneficial data that could fundamentally change how growers assess and maintain healthy plants,” said Michael Kahn, MCR Labs founder and CEO. “Seeing trends and correcting imbalances early could mean bigger yields and better quality output.” By launching testing services beyond their state’s compliance scope, MCR Labs hopes to strengthen their role as a partner to growers and cannabis businesses looking to get the most out of their plants. “The goal in developing this test was to give our clients access to insights about nutritional deficiencies or excesses that can save them time, effort, and money spent on keeping their plants happy,” said Julie Martellini, MCR Labs scientific operations manager. MCR Labs has begun accepting samples for Plant Nutrient Analysis at their Massachusetts facility. They plan to offer this service at all of their facilities by the end of the year. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Joe Crinkley +1 857-230-0839 joe@mcrlabs.com Company Website http://mcrlabs.com

October 20, 2021 12:05 PM Eastern Daylight Time

Premium UK CBD brand Infused Amphora expands and launches in Hong Kong

Infused Amphora

Premium British CBD wellness company, Amphora Health, is pleased to announce they have secured the company’s first sales in Hong Kong of its 100% owned brand, Infused Amphora. With this first step into the Asian marketplace Amphora Health is initially offering two product categories under the Infused Amphora brand: ultra-high strength CBD infused oil tinctures and premium organic CBD vape cartridges. CBD consumers in Hong Kong are now able to purchase any of the company’s four high-quality, effects-based formulations through our partnership with Smart CBD, the only CBD multi-retail store in Hong Kong. These formulations are intended to support consumers with individual wellness goals and consist of the following four effects: INSPIRE: delivers an earthy and herbal vibe with lilac undertones, and a lemon-pepper nose. Allowing you to brainstorm, be unique, think differently or create a masterpiece. PEACE: combines a sweet woody flavour with a tickle of green peppercorn and a clean grapefruit finish. You will feel the embrace of a warm hug that removes the edge off stress. MEND: allows you to slip into a relaxing bath of sweet stone fruits, savory herbs and a pine finish. Find relief from tension and release muscular aches and pains. ZZZ: offers the sensation of walking through a forest after the rain. Like the perfect cup of tea to be taken at bedtime - hints of juniper and lemon. Removing the day’s worries and helping you to drift into a peaceful sleep. Throughout 2020 Amphora Health launched a broad range of CBD products across the United Kingdom and the European Union. The company is now leveraging its global network of fulfillment and supplier partners to enable its international growth. Their strategic entry into Hong Kong enables Amphora Health to take advantage of the expected global CBD & Hemp wellness market which is forecasted to reach USD $13.4 billion by 2028 – with the Asia Pacific region representing a sizeable portion of this opportunity. Their Infused Amphora product line is available through retail locations and online marketplaces. Angus Taylor, CEO of Amphora Health, commented “Over the past year we have focused on establishing Infused Amphora as a leading CBD brand in the United Kingdom and European Union. From this strong foundation we are now positioning Infused Amphora as a leading global CBD brand with plans to extend our business strategy to other countries in the Asia-Pacific region. Hong Kong presents Amphora Health with a tremendous opportunity to expand our presence with a range of additional products, including a therapeutic sports cream and CBD-infused mints.” David Wong, Co-Founder of SmartCBD, commented “We are thrilled to partner with Amphora Health and establish their presence in Hong Kong. Our team has more than 10 years of retail experience in health and supplements, while our E-Commerce websites have over 1.5 million cumulative users, and we also have three physical stores at the heart of Hong Kong's bustling areas Mong Kok, Kwun Tong and Causeway Bay. SmartCBD has a deep understanding of the health needs of the Hong Kong people. In our experience, the local CBD market is growing steadily as consumers seek out natural wellness solutions. It is exciting to be at the spearhead of this emerging industry while working with a brand partner we trust.” Amphora Health is actively looking to collaborate and partner with potential Brand Ambassadors on the many potential wellness benefits and financial opportunities of hemp-derived CBD oil. If interested, please send inquiries to clientcare@infusedamphora.com ENDS 1 Each product comes with a Eurofins Certificate of Analysis and carries the ILAC (International Laboratory Accreditation Cooperation) Mutual Recognition Arrangement and UKAS (UK's National Accreditation Body) marks. About Amphora Health and the Infused Amphora Brand Infused Amphora is a premium CBD wellness brand formulated in the UK, owned by Amphora Health LTD, a global health-and-wellness product entity business. Infused Amphora is dedicated to providing all-natural, symptom-targeting and high-quality CBD products. Elevating users on their wellness journeys, each product is designed with a specific purpose, whether it’s sparking creativity, relieving stress, calming their thoughts before bed, or soothing muscle aches & pains. With only two simple ingredients (CBD distillate sourced from 100% organically grown hemp and plant-based terpenes to supply that beneficial entourage effect) we keep our customer’s health as our top priority. All of our products have zero harmful additives & solvents, are nicotine-free, pesticide-free, and THC-free to ensure no intoxicating effects, just pure bliss in every breath. About Smart Supplement Smart Supplement was established in 2015, and over the past six years has quickly risen to become one of the most popular platforms in Hong Kong for sports and health supplements. Smart Supplement actively seeks innovative, high-quality health products to present to its customers, and embarked on their journey into CBD products in 2020 with an all-new CBD-focused sub-brand - SmartCBD. Contact Details Amphora Health LTD Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.infusedamphora.com

October 20, 2021 09:00 AM Eastern Daylight Time

Image

Enhanced Benchmarking Capabilities Added to SullivanCotter’s Provider Performance Management Technology™

SullivanCotter

SullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs, workforce solutions, and technology and data products for the health care industry and not-for-profit sector, announces significant benchmarking enhancements to its growing Provider Performance Management Technology TM (PPMT™) platform. PPMT is an industry-first, cloud-based product that engages clinicians and informs leaders through transparent performance-based compensation administration, contract management, and analytical and reporting capabilities. PPMT’s fall product release includes new configurability options for its already powerful benchmarking capabilities, including the ability to select months for productivity benchmarks and identify and benchmark physicians who specialize in multiple service areas. “Our latest enhancement allows users to remove abnormally low productivity months, particularly like we’ve seen with COVID-19, to make the data set more relevant. This can also be beneficial when clinicians take a leave of absence and more,” said Shelly Slowiak, Director, Product Support, PPMT, SullivanCotter. PPMT’s current functionality enables clients to view both individual and collective physician performance relative to their own custom organizational benchmarks. This allows physicians and leaders to monitor real-time productivity and compare to the organization’s key compensation productivity thresholds. In addition to displaying wRVU productivity, users may compare total cash compensation (TCC) and metrics to external and internal benchmarks for both full-time and split clinical roles. Designed to address a spectrum of physician, leadership and other key stakeholder needs, PPMT combines years of health care compensation insight and expertise with an intuitive and automated technology platform to help drive provider performance and support the transition from volume- to value-based care. “Based on the evolving needs of our clients, SullivanCotter continues to invest in and improve our technology products. Alongside Benchmarks360™, which enables clients to analyze and visualize compensation, clinical productivity, and workforce perceptions, we continue to offer our clients additional ways to benchmark pay and productivity,” said David Schwietz, Chief Information Officer, SullivanCotter. For more information on these enhancements or our entire suite of Provider Performance Management Technology™, visit www.sullivancotter.com/PPMT or contact us at 888.739.7039. About SullivanCotter SullivanCotter partners with health care and other not-for-profit organizations to understand what drives performance and improve outcomes through the development and implementation of integrated workforce strategies. Using our time-tested methodologies and industry-leading research and information, we provide data-driven insights, expertise, data and technology products to help organizations align business strategy and performance objectives – enabling our clients to deliver on their mission, vision and values. Contact Details Becky Lorentz +1 314-414-3719 beckylorentz@sullivancotter.com Company Website https://sullivancotter.com

October 19, 2021 11:00 AM Eastern Daylight Time

13th Annual American Kidney Fund Gala, The Hope Affair, Honors 50 Years of Fighting Kidney Disease While Forging the Path Ahead

American Kidney Fund

The American Kidney Fund (AKF) will host its 13th annual gala, The Hope Affair, on Wednesday, Oct. 20, at 7:30 p.m. ET. The event—virtual again this year due to the COVID-19 pandemic—will bring together patients, families, caregivers and the renal community in the only national event of its kind. The Hope Affair celebrates the inspirational individuals who fight kidney disease every day, as well as the family caregivers and health professionals who take care of them. This special online event is free and open to all who wish to attend; advance registration is required at TheHopeAffair.org. The theme for this year’s The Hope Affair is Honoring the Past. Forging the Future., a fitting way to highlight this moment in AKF’s history as the organization celebrates its 50 th anniversary. After 50 years of fighting kidney disease and helping people live healthier lives, AKF is both looking back with pride on its past achievements and reflecting on its vision for the future. The Hope Affair will be emceed by Emmy Award-winning news anchor Shawn Yancy. This event provides an opportunity to recognize the people at the heart of AKF’s work, without whom a milestone anniversary would not be possible, including this year’s honorees: Leigh-Ann Williams, an AKF Ambassador and Kidney Health Coach from New Orleans, is the 2021 AKF Hero of Hope. While undergoing dialysis at home, Leigh-Ann has continued working, traveling and pursuing her education, recently earning her Masters in Public Health from Louisiana State University. She shares AKF’s commitment to reducing health disparities that lead to high rates of kidney failure and other chronic diseases in communities of color. As an AKF Ambassador, Leigh-Ann has advocated on Capitol Hill for kidney patients across the country. Jeremy Smith of Brooklyn is the recipient of the 2021 KidneyNation Excellence Award. Jeremy took advantage of the COVID-19 lockdowns last year to change his entire lifestyle and become his healthiest in preparation for giving the gift of life. He donated his kidney to his brother, Drew, in October 2020. Not only did Jeremy fly across the country for the surgery, but he also raised more than $12,100 for AKF’s programs and services through KidneyNation, AKF’s do-it-yourself fundraising program. Sadallah Alhaj, a sixth grader from Philadelphia, is the 2021 AKF Calendar Kids Cover Artist. Born without functioning kidneys, Sadallah had a kidney transplant at age two that lasted for eight years, and he is now back on dialysis three times a week. His artwork, Fishing for a Kidney, received the most votes from the public during this year’s contest and will be featured on the cover of AKF’s 2022 calendar. “The Hope Affair is a wonderful chance to celebrate the positive progress for those living with kidney disease,” said LaVarne A. Burton, AKF President and CEO. “This year, the event provides further opportunity for reflection as we look at that progress not just in this past year, but in the 50 years since AKF was founded. With the help of passionate, dedicated and inspiring people like Leigh-Ann, Jeremy and Sadallah, the American Kidney Fund will proudly continue to fight on all fronts, for every American impacted by kidney disease for the next 50 years – and beyond.” Proceeds raised through The Hope Affair will support AKF’s prevention, early detection, financial support, disease management, clinical research, innovation and advocacy programs. The Hope Affair 2021 is made possible thanks to generous lead support from Diamond Sponsor Akebia Therapeutics and Gold Sponsor Amgen, along with many other corporate and individual supporters. A full sponsor listing can be found at TheHopeAffair.org. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck 202-470-1797 +1 978-390-1394 11921 Rockville Pike Suite 300 Rockville, MD 20852 AKF@jpa.com Company Website https://www.kidneyfund.org/

October 19, 2021 09:00 AM Eastern Daylight Time

ALLIED CORP SIGNS MAJOR SUPPLY AGREEMENT WITH US MULTI STATE OPERATOR (MSO) AND SALES AGREE-MENT FOR ALLIED’S CBD BRANDS

Allied Corp

Allied Corp. ("Allied" or the “Company”) ( OTCQB: ALID ) is pleased to announce the signing of what we believe to be another major supply agreement for the 2022 calendar year. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States only allows for THC levels to be less than 0.3%). In addition to the quantities contemplated in the October 07, 2021 press release, on October 17, 2021, Allied signed another supply contract with a US Multi State Operator for 12,000 kilograms of dried cannabis flower for the 2022 calendar year. This product will be supplied starting in January 2022 and will be the beginning of another monthly recurring supply contract. In addition to this, Allied has also signed a purchase order for its branded CBD products in the United States. Through this agreement, Allied products will be sent to retail stores within the states of California and Nevada. These products include: Tactical Relief™ Liberty CBD Tincture Tactical Relief™ Rapid Recovery Roll on Oil Tactical Relief™ Battle Balm Tactical Relief™ Fizzy Tabs Tactical Relief™ Tactical Hydration Tactical Relief™ Quick Hit Gummies Equilibrium Bio™ CBD Tincture Equilibrium Bio™ Rapid Recovery Roll on Oil Equilibrium Bio™ Athletic Rub Equilibrium Bio™ Fizzy Tabs Equilibrium Bio™ Hydration Drinks Equilibrium Bio™ Gummies MaXXa™ Skin Structure MaXXa™ Eye Recover Maxxa™ Glossy Lip Recover MaXXa™ Skin Designer MaXXa™ Vitamin Absolute MaXXa™ Absolute Recover Under the 2018 Farm Bill, the United States legalized the ability to sell CBD based natural health products. The THC threshold limit is set at 0.3%THC. All of Allied’s products are currently within the legal thresholds and within compliance of the national laws in the United States. “We are ready to provide large volumes of high quality cannabis to the international marketplace. With several supply contracts signed for the 2022 calendar year, we are ready to start shipping when Colombia allows. Allied harvests on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week. In addition to this, we are offering attractive terms to approved off take partners to offer what we believe to be a de-risked pricing structure to the sales cycle.” said Mr. Calum Hughes, CEO and Chairman of Allied Corp. About Allied Corp. - https://allied.health/ Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD. Investor Relations:ir@allied.health1-877-255-4337 Forward-Looking Statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or the United States ( “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and the introduction of TACTICAL RELIEF™ branded products. There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov. Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws. Contact Details Allied Corp Investor Relations +1 877-255-4337 ir@allied.health Company Website https://allied.health/

October 19, 2021 05:55 AM Pacific Daylight Time

Healthcare

Kadimastem Raises $5 million In Private Placement

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

AmeriLife Appoints Ford Stokes Senior Vice President, Annuity Marketing

AROYA Enhances Cannabis Production Platform with New Mobile Dashboard

New Plant Nutrient Analysis at MCR Labs Can Help Growers Save Money and Improve Yield

Premium UK CBD brand Infused Amphora expands and launches in Hong Kong

Enhanced Benchmarking Capabilities Added to SullivanCotter’s Provider Performance Management Technology™

13th Annual American Kidney Fund Gala, The Hope Affair, Honors 50 Years of Fighting Kidney Disease While Forging the Path Ahead

ALLIED CORP SIGNS MAJOR SUPPLY AGREEMENT WITH US MULTI STATE OPERATOR (MSO) AND SALES AGREE-MENT FOR ALLIED’S CBD BRANDS